Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.

NCT Number	NCT07098806
Lead Sponsor	Plus Therapeutics
Conditions	Leptomeningeal Metastasis
Enrollment	24 participants
Start Date	2025-07-02
Primary Completion	2026-10-02 (estimated)
Study Completion	2031-10-02 (estimated)
Updated on ClinicalTrials.gov	2025-08-01